Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

pembrolizumab 95Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 59Cisplatin 56Biopsy 56Nivolumab 51Radiotherapy 47Cyclophosphamide 44Paclitaxel 43Radiation 36durvalumab 33Gemcitabine 31olaparib 30Dexamethasone 30Etoposide 29Doxorubicin 28atezolizumab 26Taxes 25Rituximab 25Docetaxel 25Ipilimumab 24Bevacizumab 24Vincristine 23Lenalidomide 23Pemetrexed 22Cytarabine 22X-Rays 21Radiotherapy, Intensity-Modulated 21Prednisone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × isatuximab × 90 days × Clear all
NCT04430894 2026-06-03

KRDI in Transplant-Eligible MM

Massachusetts General Hospital

Phase 2 Active not recruiting
50 enrolled 20 charts
Plasma cell

Multiple Myeloma

NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
6 enrolled 5 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡